Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Meningioma | 21 | 2024 | 1221 | 4.860 |
Why?
|
Brain Neoplasms | 77 | 2024 | 9071 | 4.640 |
Why?
|
Radiosurgery | 23 | 2024 | 1328 | 3.930 |
Why?
|
Meningeal Neoplasms | 17 | 2024 | 1252 | 3.550 |
Why?
|
Cranial Irradiation | 12 | 2024 | 385 | 2.980 |
Why?
|
Radiation Injuries | 16 | 2024 | 1181 | 2.870 |
Why?
|
Neuroma, Acoustic | 6 | 2023 | 456 | 2.810 |
Why?
|
Photons | 14 | 2024 | 572 | 2.760 |
Why?
|
Glioma | 18 | 2024 | 3493 | 2.600 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 28 | 2024 | 1643 | 2.380 |
Why?
|
Radiotherapy Dosage | 42 | 2024 | 2865 | 2.140 |
Why?
|
Protons | 13 | 2023 | 1073 | 1.870 |
Why?
|
Hypopituitarism | 4 | 2023 | 254 | 1.430 |
Why?
|
Pituitary Neoplasms | 8 | 2023 | 1321 | 1.310 |
Why?
|
Medulloblastoma | 4 | 2022 | 658 | 1.270 |
Why?
|
Cerebellar Neoplasms | 3 | 2022 | 571 | 1.200 |
Why?
|
Radiotherapy | 6 | 2021 | 1494 | 1.160 |
Why?
|
Radiotherapy, Adjuvant | 10 | 2023 | 1776 | 1.120 |
Why?
|
Melanoma | 16 | 2023 | 5719 | 1.080 |
Why?
|
Intracranial Arteriovenous Malformations | 3 | 2016 | 360 | 1.060 |
Why?
|
Uveal Neoplasms | 4 | 2020 | 343 | 1.050 |
Why?
|
Neurofibromatosis 2 | 2 | 2023 | 387 | 1.000 |
Why?
|
Radiotherapy, Intensity-Modulated | 9 | 2017 | 784 | 0.940 |
Why?
|
Astrocytoma | 4 | 2022 | 772 | 0.930 |
Why?
|
Oligodendroglioma | 2 | 2022 | 273 | 0.870 |
Why?
|
Hearing Loss | 2 | 2022 | 784 | 0.850 |
Why?
|
Labyrinthine Fluids | 1 | 2022 | 15 | 0.840 |
Why?
|
World Health Organization | 5 | 2024 | 1328 | 0.830 |
Why?
|
Glioblastoma | 11 | 2024 | 3459 | 0.800 |
Why?
|
Necrosis | 8 | 2024 | 1617 | 0.790 |
Why?
|
Neoplasm Recurrence, Local | 16 | 2024 | 9373 | 0.760 |
Why?
|
Volition | 1 | 2021 | 61 | 0.740 |
Why?
|
Dangerous Behavior | 1 | 2021 | 65 | 0.740 |
Why?
|
Organs at Risk | 4 | 2024 | 352 | 0.720 |
Why?
|
Tinnitus | 1 | 2023 | 197 | 0.690 |
Why?
|
Retrospective Studies | 53 | 2024 | 81515 | 0.680 |
Why?
|
Law Enforcement | 1 | 2021 | 112 | 0.670 |
Why?
|
Paraganglioma, Extra-Adrenal | 1 | 2019 | 47 | 0.660 |
Why?
|
Radiotherapy, Conformal | 5 | 2014 | 533 | 0.660 |
Why?
|
Humans | 179 | 2024 | 765956 | 0.650 |
Why?
|
Adenoma | 5 | 2016 | 2152 | 0.620 |
Why?
|
Disease Progression | 17 | 2023 | 13631 | 0.620 |
Why?
|
Scattering, Radiation | 3 | 2017 | 482 | 0.620 |
Why?
|
Deafness | 1 | 2022 | 460 | 0.610 |
Why?
|
Optic Nerve | 3 | 2024 | 567 | 0.600 |
Why?
|
Combined Modality Therapy | 17 | 2022 | 8529 | 0.600 |
Why?
|
Neurocytoma | 1 | 2018 | 28 | 0.590 |
Why?
|
Head and Neck Neoplasms | 6 | 2024 | 2921 | 0.590 |
Why?
|
Lymphoma, Follicular | 1 | 2022 | 459 | 0.580 |
Why?
|
Middle Aged | 80 | 2024 | 223004 | 0.580 |
Why?
|
Adult | 77 | 2024 | 223038 | 0.580 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2018 | 614 | 0.570 |
Why?
|
Neurosecretory Systems | 1 | 2019 | 222 | 0.570 |
Why?
|
Emergency Treatment | 1 | 2021 | 494 | 0.570 |
Why?
|
Eye Neoplasms | 4 | 2024 | 304 | 0.560 |
Why?
|
Iris Neoplasms | 1 | 2017 | 13 | 0.550 |
Why?
|
Radiation Oncology | 4 | 2024 | 569 | 0.550 |
Why?
|
Neoplasms, Second Primary | 4 | 2013 | 1050 | 0.540 |
Why?
|
Behavior, Addictive | 1 | 2022 | 423 | 0.540 |
Why?
|
Lung Neoplasms | 17 | 2023 | 13451 | 0.530 |
Why?
|
Watchful Waiting | 1 | 2020 | 493 | 0.520 |
Why?
|
Brain Stem | 2 | 2019 | 853 | 0.500 |
Why?
|
Follow-Up Studies | 24 | 2024 | 39194 | 0.500 |
Why?
|
Male | 88 | 2024 | 363691 | 0.490 |
Why?
|
Limbus Corneae | 1 | 2017 | 144 | 0.480 |
Why?
|
Female | 97 | 2024 | 396101 | 0.480 |
Why?
|
Optic Nerve Diseases | 1 | 2018 | 343 | 0.480 |
Why?
|
Retinoblastoma | 2 | 2014 | 316 | 0.470 |
Why?
|
Waiting Lists | 1 | 2019 | 777 | 0.470 |
Why?
|
Dermoscopy | 1 | 2015 | 73 | 0.470 |
Why?
|
Skull Base Neoplasms | 4 | 2024 | 276 | 0.460 |
Why?
|
Aged | 63 | 2024 | 171114 | 0.460 |
Why?
|
Monte Carlo Method | 5 | 2016 | 1238 | 0.450 |
Why?
|
Treatment Outcome | 30 | 2023 | 65189 | 0.450 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 10 | 2023 | 5389 | 0.450 |
Why?
|
Receptor Protein-Tyrosine Kinases | 4 | 2017 | 1624 | 0.440 |
Why?
|
Tumor Burden | 6 | 2020 | 1885 | 0.440 |
Why?
|
Neoplasms, Radiation-Induced | 3 | 2013 | 540 | 0.430 |
Why?
|
Radiation Dosage | 4 | 2024 | 1944 | 0.430 |
Why?
|
Positron-Emission Tomography | 7 | 2018 | 6547 | 0.410 |
Why?
|
Retinal Neoplasms | 1 | 2014 | 147 | 0.400 |
Why?
|
Telephone | 1 | 2016 | 627 | 0.400 |
Why?
|
Kaplan-Meier Estimate | 9 | 2020 | 6499 | 0.400 |
Why?
|
Safety Management | 1 | 2017 | 763 | 0.390 |
Why?
|
Hair | 1 | 2015 | 508 | 0.380 |
Why?
|
Brain | 16 | 2024 | 27178 | 0.370 |
Why?
|
Relative Biological Effectiveness | 5 | 2017 | 299 | 0.360 |
Why?
|
Disease-Free Survival | 7 | 2022 | 6832 | 0.360 |
Why?
|
Aged, 80 and over | 32 | 2020 | 59488 | 0.350 |
Why?
|
Isocitrate Dehydrogenase | 4 | 2019 | 954 | 0.350 |
Why?
|
Genes, BRCA1 | 4 | 2002 | 750 | 0.350 |
Why?
|
Alcoholism | 1 | 2021 | 1975 | 0.350 |
Why?
|
Young Adult | 26 | 2022 | 59886 | 0.350 |
Why?
|
Meningeal Carcinomatosis | 2 | 2021 | 65 | 0.350 |
Why?
|
Faculty, Medical | 1 | 2018 | 1219 | 0.340 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2015 | 1240 | 0.340 |
Why?
|
Program Evaluation | 1 | 2018 | 2499 | 0.340 |
Why?
|
Microscopy | 1 | 2015 | 901 | 0.340 |
Why?
|
Visual Acuity | 4 | 2015 | 2708 | 0.340 |
Why?
|
Models, Biological | 5 | 2014 | 9443 | 0.340 |
Why?
|
Image Interpretation, Computer-Assisted | 3 | 2015 | 3358 | 0.330 |
Why?
|
Acromegaly | 2 | 2014 | 316 | 0.330 |
Why?
|
Pattern Recognition, Automated | 1 | 2015 | 978 | 0.320 |
Why?
|
ras Proteins | 1 | 2014 | 1053 | 0.320 |
Why?
|
Radiometry | 5 | 2017 | 804 | 0.310 |
Why?
|
Optic Nerve Neoplasms | 1 | 2009 | 45 | 0.310 |
Why?
|
Prognosis | 24 | 2024 | 29921 | 0.310 |
Why?
|
Karnofsky Performance Status | 6 | 2020 | 163 | 0.310 |
Why?
|
Chordoma | 3 | 2018 | 343 | 0.310 |
Why?
|
Stem Cell Transplantation | 1 | 2017 | 1602 | 0.300 |
Why?
|
Algorithms | 11 | 2021 | 14071 | 0.300 |
Why?
|
Mammaplasty | 1 | 2018 | 1264 | 0.290 |
Why?
|
Treatment Failure | 3 | 2019 | 2652 | 0.290 |
Why?
|
Hippocampus | 1 | 2020 | 3775 | 0.280 |
Why?
|
Immunotherapy | 5 | 2020 | 4752 | 0.280 |
Why?
|
Occupational Exposure | 1 | 2017 | 1805 | 0.280 |
Why?
|
Patient Satisfaction | 1 | 2019 | 3475 | 0.280 |
Why?
|
Mammary Neoplasms, Experimental | 2 | 2009 | 498 | 0.270 |
Why?
|
Neoplasms, Multiple Primary | 3 | 2014 | 587 | 0.260 |
Why?
|
Adolescent | 22 | 2022 | 88832 | 0.260 |
Why?
|
Small Cell Lung Carcinoma | 3 | 2022 | 451 | 0.260 |
Why?
|
Lymphatic Irradiation | 1 | 2005 | 110 | 0.240 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 11868 | 0.240 |
Why?
|
Breast Neoplasms | 14 | 2020 | 21056 | 0.240 |
Why?
|
Substance-Related Disorders | 1 | 2021 | 4415 | 0.230 |
Why?
|
Pain | 1 | 2019 | 5077 | 0.230 |
Why?
|
Ki-67 Antigen | 2 | 2017 | 629 | 0.220 |
Why?
|
Chondrosarcoma | 2 | 2018 | 301 | 0.220 |
Why?
|
Neoplasms | 8 | 2022 | 22340 | 0.220 |
Why?
|
Cognition Disorders | 2 | 2016 | 3967 | 0.220 |
Why?
|
Infratentorial Neoplasms | 2 | 2015 | 94 | 0.220 |
Why?
|
Whole Body Imaging | 1 | 2005 | 281 | 0.210 |
Why?
|
Time Factors | 11 | 2021 | 40065 | 0.210 |
Why?
|
Brachytherapy | 2 | 2022 | 1222 | 0.210 |
Why?
|
Quality of Life | 9 | 2024 | 13461 | 0.210 |
Why?
|
Proto-Oncogene Proteins | 2 | 2014 | 4520 | 0.210 |
Why?
|
Chromosomes, Human, Pair 19 | 2 | 2019 | 350 | 0.210 |
Why?
|
Pituitary Gland | 2 | 2019 | 631 | 0.210 |
Why?
|
Headache | 2 | 2022 | 1259 | 0.210 |
Why?
|
Survival Rate | 8 | 2018 | 12795 | 0.200 |
Why?
|
Survival Analysis | 8 | 2021 | 10070 | 0.200 |
Why?
|
Postoperative Period | 4 | 2020 | 1816 | 0.200 |
Why?
|
Paraganglioma | 1 | 2024 | 143 | 0.200 |
Why?
|
Movement | 2 | 2010 | 1462 | 0.200 |
Why?
|
Dose-Response Relationship, Radiation | 3 | 2024 | 869 | 0.190 |
Why?
|
Protein Kinase Inhibitors | 2 | 2015 | 5696 | 0.190 |
Why?
|
Gastrointestinal Neoplasms | 3 | 2019 | 961 | 0.190 |
Why?
|
Cochlea | 2 | 2022 | 847 | 0.190 |
Why?
|
Chromosomes, Human, Pair 1 | 2 | 2019 | 640 | 0.190 |
Why?
|
Biomedical Research | 1 | 2017 | 3458 | 0.190 |
Why?
|
Adenocarcinoma | 4 | 2022 | 6364 | 0.190 |
Why?
|
Quality of Health Care | 2 | 2016 | 4300 | 0.190 |
Why?
|
Central Nervous System Neoplasms | 2 | 2023 | 916 | 0.180 |
Why?
|
Glaucoma, Neovascular | 1 | 2020 | 37 | 0.180 |
Why?
|
Image Enhancement | 2 | 2015 | 2858 | 0.180 |
Why?
|
Hyperoxaluria | 1 | 2000 | 33 | 0.180 |
Why?
|
Craniopharyngioma | 1 | 2023 | 276 | 0.170 |
Why?
|
Gangrene | 1 | 2000 | 92 | 0.170 |
Why?
|
Leg Ulcer | 1 | 2000 | 70 | 0.170 |
Why?
|
Skin Diseases, Vascular | 1 | 2000 | 42 | 0.170 |
Why?
|
Prospective Studies | 10 | 2024 | 54806 | 0.170 |
Why?
|
Vision Disorders | 2 | 2022 | 1087 | 0.170 |
Why?
|
Probability | 3 | 2021 | 2475 | 0.170 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2023 | 2054 | 0.170 |
Why?
|
Procarbazine | 1 | 2019 | 172 | 0.170 |
Why?
|
Magnetic Resonance Imaging | 11 | 2024 | 36532 | 0.170 |
Why?
|
Lomustine | 1 | 2019 | 60 | 0.170 |
Why?
|
Molecular Targeted Therapy | 3 | 2021 | 2822 | 0.170 |
Why?
|
Models, Theoretical | 2 | 2011 | 3564 | 0.170 |
Why?
|
Actuarial Analysis | 1 | 2019 | 366 | 0.160 |
Why?
|
Linear Energy Transfer | 1 | 2020 | 147 | 0.160 |
Why?
|
Mutation | 10 | 2020 | 30196 | 0.160 |
Why?
|
Pain Measurement | 2 | 2019 | 3561 | 0.160 |
Why?
|
Fatigue | 2 | 2023 | 1549 | 0.160 |
Why?
|
Neurosurgical Procedures | 4 | 2020 | 2074 | 0.160 |
Why?
|
Analysis of Variance | 4 | 2014 | 6203 | 0.150 |
Why?
|
Genes, BRCA2 | 1 | 2002 | 588 | 0.150 |
Why?
|
Lymphatic Metastasis | 2 | 2005 | 2887 | 0.150 |
Why?
|
Lymphopenia | 1 | 2021 | 297 | 0.150 |
Why?
|
Microscopy, Fluorescence | 1 | 2005 | 2627 | 0.150 |
Why?
|
Radiography | 3 | 2014 | 6919 | 0.150 |
Why?
|
Hearing | 1 | 2022 | 505 | 0.150 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2021 | 352 | 0.150 |
Why?
|
Thyroid Function Tests | 1 | 2019 | 293 | 0.150 |
Why?
|
Nasopharyngeal Neoplasms | 2 | 2019 | 296 | 0.150 |
Why?
|
Skull Neoplasms | 1 | 2018 | 173 | 0.150 |
Why?
|
Carcinoma, Renal Cell | 4 | 2018 | 3181 | 0.140 |
Why?
|
Dacarbazine | 2 | 2018 | 552 | 0.140 |
Why?
|
DNA, Neoplasm | 2 | 2003 | 1742 | 0.140 |
Why?
|
Nitrosourea Compounds | 1 | 2017 | 32 | 0.140 |
Why?
|
Cognition | 1 | 2015 | 7048 | 0.140 |
Why?
|
Mitotic Index | 1 | 2017 | 159 | 0.140 |
Why?
|
Vincristine | 1 | 2019 | 1039 | 0.140 |
Why?
|
Preservation, Biological | 1 | 2017 | 26 | 0.140 |
Why?
|
Neurosciences | 1 | 2022 | 385 | 0.140 |
Why?
|
Radiation Tolerance | 1 | 2018 | 475 | 0.130 |
Why?
|
Career Mobility | 1 | 2018 | 259 | 0.130 |
Why?
|
Spinal Neoplasms | 2 | 2014 | 708 | 0.130 |
Why?
|
Anisotropy | 2 | 2024 | 1284 | 0.130 |
Why?
|
Intention to Treat Analysis | 1 | 2017 | 416 | 0.130 |
Why?
|
Neoplasm Proteins | 4 | 2005 | 3596 | 0.130 |
Why?
|
Methionine | 1 | 2018 | 569 | 0.130 |
Why?
|
Massachusetts | 3 | 2021 | 8871 | 0.120 |
Why?
|
Tomography, X-Ray Computed | 7 | 2015 | 20660 | 0.120 |
Why?
|
Oxygen Radioisotopes | 1 | 2015 | 60 | 0.120 |
Why?
|
Child | 13 | 2023 | 80563 | 0.120 |
Why?
|
Multivariate Analysis | 6 | 2020 | 12057 | 0.120 |
Why?
|
Sensitivity and Specificity | 5 | 2016 | 14652 | 0.120 |
Why?
|
Cell Proliferation | 3 | 2017 | 10429 | 0.120 |
Why?
|
Cohort Studies | 9 | 2021 | 41647 | 0.120 |
Why?
|
Misonidazole | 1 | 2014 | 33 | 0.120 |
Why?
|
Fovea Centralis | 1 | 2015 | 126 | 0.120 |
Why?
|
Chromosome Deletion | 1 | 2019 | 1385 | 0.120 |
Why?
|
Prostatic Neoplasms | 5 | 2017 | 11083 | 0.120 |
Why?
|
Receptor, erbB-2 | 4 | 2020 | 2593 | 0.120 |
Why?
|
Glutarates | 1 | 2016 | 243 | 0.120 |
Why?
|
Choroid Neoplasms | 1 | 2015 | 175 | 0.120 |
Why?
|
Genes, ras | 1 | 2017 | 658 | 0.110 |
Why?
|
Carbazoles | 1 | 2015 | 229 | 0.110 |
Why?
|
Cerebral Hemorrhage | 2 | 2017 | 2648 | 0.110 |
Why?
|
Health Physics | 1 | 2014 | 35 | 0.110 |
Why?
|
Physics | 1 | 2014 | 92 | 0.110 |
Why?
|
Travel | 1 | 2019 | 806 | 0.110 |
Why?
|
Kidney Neoplasms | 4 | 2018 | 4274 | 0.110 |
Why?
|
Rhabdoid Tumor | 1 | 2015 | 209 | 0.110 |
Why?
|
Universities | 1 | 2018 | 998 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2017 | 723 | 0.100 |
Why?
|
Mentors | 1 | 2018 | 671 | 0.100 |
Why?
|
Genetic Markers | 4 | 2017 | 2601 | 0.100 |
Why?
|
Practice Guidelines as Topic | 2 | 2021 | 7425 | 0.100 |
Why?
|
Turner Syndrome | 1 | 2014 | 129 | 0.100 |
Why?
|
Cancer Care Facilities | 1 | 2016 | 426 | 0.100 |
Why?
|
Risk | 3 | 2021 | 9591 | 0.100 |
Why?
|
Teratoma | 1 | 2015 | 401 | 0.100 |
Why?
|
Phantoms, Imaging | 2 | 2015 | 2475 | 0.100 |
Why?
|
Supratentorial Neoplasms | 1 | 2013 | 153 | 0.100 |
Why?
|
Scalp | 1 | 2015 | 388 | 0.100 |
Why?
|
Proportional Hazards Models | 5 | 2020 | 12509 | 0.100 |
Why?
|
Cell Hypoxia | 1 | 2014 | 647 | 0.100 |
Why?
|
Reproducibility of Results | 5 | 2016 | 20125 | 0.100 |
Why?
|
Pilot Projects | 3 | 2021 | 8733 | 0.100 |
Why?
|
Antineoplastic Agents | 5 | 2023 | 13648 | 0.100 |
Why?
|
Growth | 1 | 2014 | 365 | 0.100 |
Why?
|
Remission Induction | 2 | 2023 | 2411 | 0.100 |
Why?
|
Ovarian Neoplasms | 4 | 2020 | 4900 | 0.100 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2024 | 5337 | 0.090 |
Why?
|
Transplantation, Autologous | 1 | 2017 | 2120 | 0.090 |
Why?
|
Headache Disorders, Secondary | 1 | 2011 | 34 | 0.090 |
Why?
|
SEER Program | 2 | 2013 | 1446 | 0.090 |
Why?
|
Salvage Therapy | 1 | 2018 | 1272 | 0.090 |
Why?
|
Risk Assessment | 4 | 2024 | 24283 | 0.090 |
Why?
|
Gamma Rays | 1 | 2012 | 324 | 0.090 |
Why?
|
Rupture, Spontaneous | 1 | 2011 | 359 | 0.090 |
Why?
|
Thyrotropin | 1 | 2014 | 841 | 0.090 |
Why?
|
Ependymoma | 1 | 2013 | 310 | 0.090 |
Why?
|
Neoplasm, Residual | 2 | 2018 | 1009 | 0.090 |
Why?
|
Patient Positioning | 1 | 2013 | 328 | 0.090 |
Why?
|
Retinal Detachment | 1 | 2014 | 426 | 0.090 |
Why?
|
Prevalence | 4 | 2019 | 15839 | 0.080 |
Why?
|
Bone Transplantation | 1 | 2015 | 920 | 0.080 |
Why?
|
Medical Oncology | 1 | 2021 | 2339 | 0.080 |
Why?
|
Genes, p53 | 2 | 2005 | 711 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2020 | 10729 | 0.080 |
Why?
|
Retreatment | 1 | 2011 | 598 | 0.080 |
Why?
|
Skin Neoplasms | 3 | 2019 | 5849 | 0.080 |
Why?
|
Risk Factors | 9 | 2019 | 74836 | 0.080 |
Why?
|
Cranial Nerve Injuries | 1 | 2009 | 27 | 0.080 |
Why?
|
Neoplasm Invasiveness | 1 | 2017 | 3602 | 0.080 |
Why?
|
Confidence Intervals | 1 | 2014 | 2910 | 0.080 |
Why?
|
Radiotherapy, High-Energy | 1 | 2009 | 226 | 0.080 |
Why?
|
Basal Ganglia | 1 | 2011 | 549 | 0.080 |
Why?
|
Abdominal Neoplasms | 1 | 2010 | 284 | 0.080 |
Why?
|
Child, Preschool | 7 | 2017 | 42500 | 0.080 |
Why?
|
Sacrum | 1 | 2010 | 270 | 0.080 |
Why?
|
Neuropsychological Tests | 2 | 2024 | 7122 | 0.070 |
Why?
|
Cause of Death | 2 | 2018 | 3708 | 0.070 |
Why?
|
Linear Models | 2 | 2017 | 5876 | 0.070 |
Why?
|
Nausea | 2 | 2021 | 680 | 0.070 |
Why?
|
Gene Amplification | 2 | 2018 | 1091 | 0.070 |
Why?
|
BRCA2 Protein | 3 | 2001 | 800 | 0.070 |
Why?
|
Visual Perception | 1 | 2016 | 1394 | 0.070 |
Why?
|
Piperidines | 1 | 2015 | 1664 | 0.070 |
Why?
|
Physician-Patient Relations | 1 | 2020 | 3278 | 0.070 |
Why?
|
Orbital Neoplasms | 1 | 2009 | 223 | 0.070 |
Why?
|
Transillumination | 1 | 2006 | 20 | 0.070 |
Why?
|
Bacterial Infections | 1 | 2015 | 1387 | 0.070 |
Why?
|
Hospitals, General | 1 | 2011 | 802 | 0.070 |
Why?
|
Colorectal Neoplasms | 2 | 2020 | 6942 | 0.070 |
Why?
|
Receptors, Progesterone | 3 | 2020 | 1153 | 0.070 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1761 | 0.070 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2016 | 3672 | 0.070 |
Why?
|
Learning | 1 | 2016 | 1755 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 10383 | 0.060 |
Why?
|
Communication | 1 | 2020 | 3916 | 0.060 |
Why?
|
Steroids | 1 | 2011 | 933 | 0.060 |
Why?
|
Intracranial Hemorrhages | 1 | 2011 | 814 | 0.060 |
Why?
|
Lung | 1 | 2004 | 10033 | 0.060 |
Why?
|
Growth Hormone | 1 | 2008 | 566 | 0.060 |
Why?
|
Surgical Wound Infection | 1 | 2015 | 1543 | 0.060 |
Why?
|
Attention | 1 | 2016 | 2418 | 0.060 |
Why?
|
Longitudinal Studies | 2 | 2018 | 14749 | 0.060 |
Why?
|
Cell Survival | 2 | 2014 | 5746 | 0.060 |
Why?
|
Incidence | 3 | 2018 | 21480 | 0.060 |
Why?
|
BRCA1 Protein | 2 | 2020 | 1153 | 0.060 |
Why?
|
Genes, p16 | 1 | 2005 | 157 | 0.060 |
Why?
|
Uncertainty | 2 | 2021 | 761 | 0.060 |
Why?
|
Radiopharmaceuticals | 1 | 2014 | 2699 | 0.060 |
Why?
|
Recurrence | 1 | 2017 | 8501 | 0.060 |
Why?
|
Qualitative Research | 1 | 2016 | 3138 | 0.060 |
Why?
|
Anxiety | 1 | 2019 | 4668 | 0.060 |
Why?
|
Chromosomes, Human, Pair 10 | 1 | 2005 | 274 | 0.060 |
Why?
|
DNA Mutational Analysis | 4 | 2015 | 4108 | 0.060 |
Why?
|
Alopecia | 1 | 2009 | 414 | 0.060 |
Why?
|
Transcription Factors | 3 | 2015 | 12131 | 0.060 |
Why?
|
Bacteria | 1 | 2015 | 2209 | 0.060 |
Why?
|
Growth Disorders | 1 | 2009 | 633 | 0.060 |
Why?
|
Neoplasm Staging | 2 | 2017 | 11206 | 0.050 |
Why?
|
Retina | 1 | 2014 | 2657 | 0.050 |
Why?
|
Age Factors | 6 | 2019 | 18380 | 0.050 |
Why?
|
Dexamethasone | 1 | 2011 | 1963 | 0.050 |
Why?
|
Germ-Line Mutation | 2 | 2003 | 1884 | 0.050 |
Why?
|
Neoplasm Metastasis | 3 | 2021 | 4893 | 0.050 |
Why?
|
Tomography | 1 | 2005 | 443 | 0.050 |
Why?
|
Luminescent Proteins | 1 | 2005 | 839 | 0.050 |
Why?
|
Computer Simulation | 3 | 2011 | 6255 | 0.050 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 2002 | 283 | 0.050 |
Why?
|
Leukoencephalopathies | 1 | 2024 | 259 | 0.050 |
Why?
|
Nervous System Physiological Phenomena | 1 | 2022 | 113 | 0.050 |
Why?
|
Pelvis | 1 | 2005 | 738 | 0.050 |
Why?
|
Seizures | 1 | 2014 | 3000 | 0.050 |
Why?
|
Anorexia | 1 | 2021 | 153 | 0.050 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 634 | 0.040 |
Why?
|
Vascular Diseases | 1 | 2009 | 1159 | 0.040 |
Why?
|
Pancreatic Neoplasms | 2 | 2011 | 5444 | 0.040 |
Why?
|
Infant | 4 | 2014 | 36385 | 0.040 |
Why?
|
Jews | 1 | 2002 | 357 | 0.040 |
Why?
|
Ciliary Body | 1 | 2020 | 168 | 0.040 |
Why?
|
Pedigree | 3 | 2003 | 4526 | 0.040 |
Why?
|
Cesium Radioisotopes | 1 | 2019 | 38 | 0.040 |
Why?
|
Muscle, Skeletal | 1 | 2015 | 4959 | 0.040 |
Why?
|
Genotype | 1 | 2014 | 13024 | 0.040 |
Why?
|
Iris | 1 | 2020 | 232 | 0.040 |
Why?
|
Hepatitis | 1 | 2021 | 227 | 0.040 |
Why?
|
Forecasting | 1 | 2009 | 2936 | 0.040 |
Why?
|
Physicians | 1 | 2017 | 4588 | 0.040 |
Why?
|
Organ Size | 1 | 2024 | 2261 | 0.040 |
Why?
|
Tumor Microenvironment | 2 | 2022 | 3946 | 0.040 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2013 | 8927 | 0.040 |
Why?
|
Choroid | 1 | 2020 | 363 | 0.040 |
Why?
|
Fluorescent Dyes | 1 | 2006 | 1930 | 0.040 |
Why?
|
Survivors | 1 | 2009 | 2372 | 0.040 |
Why?
|
Respiration | 1 | 2004 | 1653 | 0.040 |
Why?
|
Triazines | 1 | 2020 | 307 | 0.040 |
Why?
|
Rectal Neoplasms | 2 | 2003 | 1182 | 0.040 |
Why?
|
Gene Deletion | 1 | 2005 | 2666 | 0.040 |
Why?
|
Endpoint Determination | 1 | 2020 | 591 | 0.040 |
Why?
|
Diagnostic Imaging | 2 | 2009 | 3529 | 0.040 |
Why?
|
Feasibility Studies | 3 | 2015 | 5302 | 0.040 |
Why?
|
Drug Therapy | 1 | 2020 | 504 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2021 | 561 | 0.030 |
Why?
|
Disease Management | 2 | 2019 | 2535 | 0.030 |
Why?
|
Vomiting | 1 | 2020 | 647 | 0.030 |
Why?
|
Exanthema | 1 | 2021 | 502 | 0.030 |
Why?
|
ROC Curve | 1 | 2024 | 3620 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2024 | 2354 | 0.030 |
Why?
|
Maintenance | 1 | 2016 | 25 | 0.030 |
Why?
|
Cyclotrons | 1 | 2016 | 30 | 0.030 |
Why?
|
Central Nervous System | 1 | 2023 | 1341 | 0.030 |
Why?
|
Palliative Care | 1 | 2011 | 3645 | 0.030 |
Why?
|
Iodine Radioisotopes | 1 | 2019 | 1029 | 0.030 |
Why?
|
San Francisco | 1 | 2016 | 166 | 0.030 |
Why?
|
Recombination, Genetic | 1 | 2000 | 1525 | 0.030 |
Why?
|
Data Interpretation, Statistical | 1 | 2005 | 2686 | 0.030 |
Why?
|
Pregnancy | 1 | 2017 | 30258 | 0.030 |
Why?
|
Poland | 1 | 2016 | 195 | 0.030 |
Why?
|
Radiotherapy, Computer-Assisted | 1 | 2016 | 90 | 0.030 |
Why?
|
Subtraction Technique | 2 | 2009 | 512 | 0.030 |
Why?
|
Switzerland | 1 | 2016 | 322 | 0.030 |
Why?
|
Stroke | 1 | 2017 | 9747 | 0.030 |
Why?
|
Biochemical Phenomena | 1 | 2015 | 58 | 0.030 |
Why?
|
Sacrococcygeal Region | 1 | 2014 | 52 | 0.030 |
Why?
|
Medical Records | 1 | 2020 | 1409 | 0.030 |
Why?
|
Age of Onset | 1 | 2002 | 3343 | 0.030 |
Why?
|
France | 1 | 2016 | 495 | 0.030 |
Why?
|
Florida | 1 | 2016 | 416 | 0.030 |
Why?
|
Benzamides | 1 | 2020 | 1377 | 0.030 |
Why?
|
Fever | 1 | 2021 | 1603 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2019 | 811 | 0.030 |
Why?
|
Thigh | 1 | 2015 | 238 | 0.030 |
Why?
|
Neovascularization, Pathologic | 1 | 2024 | 2631 | 0.030 |
Why?
|
Receptors, Estrogen | 2 | 2013 | 2242 | 0.030 |
Why?
|
Imidazoles | 1 | 2020 | 1162 | 0.030 |
Why?
|
Estrogens | 1 | 2020 | 1529 | 0.030 |
Why?
|
Internship and Residency | 1 | 2014 | 5946 | 0.030 |
Why?
|
Arteriovenous Malformations | 1 | 2016 | 397 | 0.030 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2005 | 1758 | 0.030 |
Why?
|
Germany | 1 | 2016 | 882 | 0.030 |
Why?
|
Sequence Analysis, DNA | 2 | 2002 | 4772 | 0.030 |
Why?
|
Diffusion Tensor Imaging | 1 | 2024 | 2416 | 0.030 |
Why?
|
Mice, Nude | 3 | 2006 | 3618 | 0.030 |
Why?
|
Colitis | 1 | 2021 | 1239 | 0.030 |
Why?
|
Permeability | 1 | 2015 | 726 | 0.030 |
Why?
|
Brain Injuries | 1 | 2024 | 2060 | 0.030 |
Why?
|
Neurofibromin 2 | 1 | 2014 | 268 | 0.030 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2003 | 2942 | 0.030 |
Why?
|
Databases, Factual | 3 | 2014 | 8067 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2017 | 1326 | 0.020 |
Why?
|
Plasmids | 1 | 1997 | 2274 | 0.020 |
Why?
|
Neurologic Examination | 1 | 2015 | 912 | 0.020 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2016 | 499 | 0.020 |
Why?
|
Hemoglobins | 1 | 2018 | 1530 | 0.020 |
Why?
|
Consensus | 1 | 2021 | 3202 | 0.020 |
Why?
|
Hyperglycemia | 1 | 2020 | 1393 | 0.020 |
Why?
|
Papillomaviridae | 1 | 1997 | 1141 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2017 | 2845 | 0.020 |
Why?
|
Time | 1 | 2013 | 550 | 0.020 |
Why?
|
Nitrogen | 1 | 2012 | 346 | 0.020 |
Why?
|
DNA, Viral | 1 | 1997 | 2199 | 0.020 |
Why?
|
Genetic Testing | 2 | 2001 | 3595 | 0.020 |
Why?
|
Piperazines | 1 | 2021 | 2549 | 0.020 |
Why?
|
Canada | 1 | 2016 | 2119 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2019 | 3537 | 0.020 |
Why?
|
Elasticity | 1 | 2012 | 652 | 0.020 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2015 | 722 | 0.020 |
Why?
|
Cryopreservation | 1 | 2015 | 728 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2021 | 3685 | 0.020 |
Why?
|
Antibiotic Prophylaxis | 1 | 2015 | 644 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2016 | 1394 | 0.020 |
Why?
|
Breast Neoplasms, Male | 1 | 2011 | 212 | 0.020 |
Why?
|
Pyridines | 1 | 2021 | 2888 | 0.020 |
Why?
|
Gene Silencing | 1 | 2015 | 1505 | 0.020 |
Why?
|
Rabbits | 1 | 2015 | 4734 | 0.020 |
Why?
|
Genes, erbB-2 | 1 | 2009 | 160 | 0.020 |
Why?
|
Mice | 5 | 2009 | 81818 | 0.020 |
Why?
|
United States | 5 | 2016 | 72898 | 0.020 |
Why?
|
Regression Analysis | 1 | 2017 | 6321 | 0.020 |
Why?
|
Angiogenesis Inhibitors | 1 | 2018 | 2056 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2014 | 2505 | 0.020 |
Why?
|
Selection Bias | 1 | 2009 | 361 | 0.020 |
Why?
|
Acute Disease | 1 | 2018 | 7232 | 0.020 |
Why?
|
Hemangiopericytoma | 1 | 2007 | 71 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2019 | 2895 | 0.020 |
Why?
|
Fibrinolytic Agents | 1 | 2017 | 2080 | 0.020 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2016 | 2423 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2016 | 18071 | 0.020 |
Why?
|
Animals | 6 | 2015 | 168759 | 0.020 |
Why?
|
Fluorescein-5-isothiocyanate | 1 | 2006 | 220 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2022 | 8041 | 0.020 |
Why?
|
Quality Assurance, Health Care | 1 | 2016 | 2172 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15398 | 0.020 |
Why?
|
Uterine Cervical Neoplasms | 1 | 1997 | 2047 | 0.020 |
Why?
|
Income | 1 | 2013 | 1874 | 0.010 |
Why?
|
Lighting | 1 | 2006 | 211 | 0.010 |
Why?
|
Intraoperative Period | 1 | 2005 | 508 | 0.010 |
Why?
|
Toxicology | 1 | 1964 | 102 | 0.010 |
Why?
|
Lymphography | 1 | 1964 | 189 | 0.010 |
Why?
|
Biopsy | 1 | 2015 | 6763 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 1998 | 5783 | 0.010 |
Why?
|
Urogenital Neoplasms | 1 | 1964 | 129 | 0.010 |
Why?
|
Cytokines | 1 | 2018 | 7421 | 0.010 |
Why?
|
Suppression, Genetic | 1 | 2003 | 190 | 0.010 |
Why?
|
Liver Abscess | 1 | 1963 | 81 | 0.010 |
Why?
|
Penile Neoplasms | 1 | 1964 | 156 | 0.010 |
Why?
|
Simplexvirus | 1 | 2005 | 807 | 0.010 |
Why?
|
Neoplasm Transplantation | 1 | 2005 | 2014 | 0.010 |
Why?
|
Blotting, Western | 1 | 2009 | 5020 | 0.010 |
Why?
|
Genes, Duplicate | 1 | 2000 | 31 | 0.010 |
Why?
|
Oxygen | 1 | 2012 | 4241 | 0.010 |
Why?
|
Polymorphism, Single-Stranded Conformational | 1 | 2000 | 325 | 0.010 |
Why?
|
Curriculum | 1 | 2014 | 3782 | 0.010 |
Why?
|
Sex Factors | 1 | 2014 | 10602 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2015 | 12976 | 0.010 |
Why?
|
Blotting, Southern | 1 | 2000 | 772 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2013 | 7836 | 0.010 |
Why?
|
False Negative Reactions | 1 | 2000 | 573 | 0.010 |
Why?
|
Logistic Models | 1 | 2013 | 13266 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2015 | 9601 | 0.010 |
Why?
|
Family Health | 1 | 2003 | 1253 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2006 | 3737 | 0.010 |
Why?
|
DNA Restriction Enzymes | 1 | 1997 | 548 | 0.010 |
Why?
|
Nucleic Acid Conformation | 1 | 2000 | 901 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2016 | 16047 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2009 | 9550 | 0.010 |
Why?
|
Genetic Vectors | 1 | 2005 | 3404 | 0.010 |
Why?
|
Cell Transformation, Viral | 1 | 1997 | 527 | 0.010 |
Why?
|
Gene Dosage | 1 | 2000 | 1216 | 0.010 |
Why?
|
Rats | 2 | 2005 | 23707 | 0.010 |
Why?
|
Gene Frequency | 1 | 2003 | 3624 | 0.010 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2001 | 1151 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 1998 | 360 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2009 | 11022 | 0.010 |
Why?
|
Gene Rearrangement | 1 | 2000 | 1144 | 0.010 |
Why?
|
Exons | 1 | 2000 | 2391 | 0.010 |
Why?
|
Retinoblastoma Protein | 1 | 1998 | 666 | 0.010 |
Why?
|
Adenoviridae | 1 | 1998 | 1092 | 0.010 |
Why?
|
Europe | 1 | 2000 | 3423 | 0.010 |
Why?
|
Carcinoma | 1 | 1964 | 2312 | 0.010 |
Why?
|
Polymorphism, Genetic | 1 | 2003 | 4247 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 1997 | 4165 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2000 | 6069 | 0.010 |
Why?
|
Cell Division | 1 | 1998 | 4475 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 1998 | 6113 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2005 | 17075 | 0.000 |
Why?
|
Carcinoma, Squamous Cell | 1 | 1964 | 4044 | 0.000 |
Why?
|
Phosphorylation | 1 | 1998 | 8278 | 0.000 |
Why?
|
Disease Models, Animal | 1 | 2005 | 18294 | 0.000 |
Why?
|
Cell Line | 1 | 1997 | 15543 | 0.000 |
Why?
|